Trevi Therapeutics Financial Statements
NASDAQ: TRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.19+0.365 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Trevi Therapeutics revenue and earnings
Trevi Therapeutics reported a net loss of $42.8 million, compared with a loss of $47.9 million a year earlier. Diluted earnings per share came in at -$0.32.
Summary generated from market data by MetaCap's automated system. Methodology
Trevi Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 49.33M | 51.52M | 33.92M | 29.91M | 32.48M | 32.49M | 26.64M | 18.41M |
| Research & Development | 33.48M | 39.38M | 23.68M | 19.83M | 22.98M | 22.33M | 19.34M | 14.07M |
| Operating Income | -49.33M | -51.52M | -33.92M | -29.91M | -32.48M | -32.49M | -26.64M | -18.41M |
| Interest Expense | 0 | 4.00K | 391.00K | 1.16M | 1.20M | 456.00K | — | 174.00K |
| Other Income (Expense) | 6.50M | 3.58M | 4.83M | 719.00K | -1.49M | -287.00K | 577.00K | -2.26M |
| Pretax Income | -42.82M | -47.94M | -29.10M | -29.19M | -33.96M | -32.78M | -26.07M | -20.67M |
| Income Tax | -64.00K | -30.00K | -32.00K | -36.00K | -21.00K | -18.00K | -18.00K | -124.00K |
| Net Income | -42.76M | -47.91M | -29.07M | -29.15M | -33.94M | -32.76M | -26.05M | -20.55M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 | -58.44 |
| EPS (Diluted) | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 | -58.44 |
| Shares Outstanding (Basic) | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M | 18.06M | 11.74M | 437.61K |
| Shares Outstanding (Diluted) | 134.75M | 101.97M | 99.03M | 64.54M | 22.84M | 18.06M | 11.74M | 437.61K |
| EBITDA | -49.18M | -51.38M | -33.80M | -29.86M | -32.43M | -32.44M | -26.61M | -18.39M |
This table shows 8 annual periods of Trevi Therapeutics's income statement, from FY 2025 back to FY 2018, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow TRVI's reporting calendar. What is a income statement?